Jonathan Kipnis

Israeli-American neuroimmunologist. Alan A. and Edith L. Wolff Distinguished Professor of Pathology and Immunology at Washington University School of Medicine in St. Louis, where he directs the Center for Brain Immunology and Glia (BIG). Moved to WashU in 2020; previously was the Harrison Distinguished Teaching Professor at the University of Virginia, where the 2015 Nature meningeal-lymphatics paper originated. The principal modern figure in the field of CNS-immunity, with a research line systematically dismantling the older immune-privileged brain framework.

Stake§

Kipnis's stake is scientific and clinical-translational. The BIG Center at WashU is one of the most ambitious neuroimmunology programmes in the U.S., with substantial NIH funding and pharmaceutical-industry collaboration. The research direction — toward understanding how meningeal-lymphatic and glymphatic systems shape CNS immunity, cognition, and disease — has implications across Alzheimer's, multiple sclerosis, autism spectrum disorders, and broader neuropsychiatric conditions.

The 2015 Nature meningeal- lymphatics paper with Antoine Louveau as first author is Kipnis's most-cited work and one of the paradigm-shift papers of post-2010 neuroscience. The independent simultaneous confirmation by Aspelund et al. gave the discovery a robustness that distinguished it from claims that turn out to be preparation artefacts; the post-2015 work has consolidated the finding into the field's standard understanding of CNS anatomy.

The broader Kipnis programme on CNS immunity began before the meningeal-lymphatics discovery and has continued substantially since. The work on T-cell-mediated effects on cognition and behaviour (including in autism-model mice), on the role of meningeal immune cells in social behaviour, and on the immune substrates of neuropsychiatric disease have together built one of the most active modern neuroimmunology programmes. The WashU move in 2020 brought the laboratory into a larger institutional infrastructure with broader clinical-translational reach.

Kipnis is the senior figure who, more than any other single researcher, has dismantled the textbook claim that the brain is immune-privileged. The empirical work has been careful and the broader claims (immune cells matter for cognition, brain disease has substantial immune components) have been delivered with the methodological rigour the field needed to take them seriously. The pharmaceutical-translation work is ongoing.